Enzyme – Talk Bio

Cereno Scientific Secures SEK 100m in Directed Share Issue and SEK 350m Loan Financing, Targeting Milestones by Q4 2027

2 weeks ago talkbio0Tagged Cardiovascular Diseases, Cereno Scientific, Clinical Development, Directed share, Histone deacetylase inhibitor, Infrequent, Loan, loan financing, milestones, portfolio, Problem, Pulmonary arterial hypertension

Cereno Scientific; SEK 100 million; Directed share issue; SEK 350 million; Loan financing; Q4 2027 milestones; HDAC inhibitor portfolio; Pulmonary arterial hypertension; Clinical development; Rare cardiovascular diseases

Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer

3 weeks ago talkbio0Tagged Biological Factors, buyback, erbB-2 Receptor, Jazz, Malignant neoplasm of stomach, milestone payments, Regulatory Filing, Royalty-Driven Model, Strategy, Ziihera, Zymeworks

Zymeworks; royalty-driven model; Ziihera; gastric cancer; HER2; biologics; milestone payments; stock buyback; biotech strategy; Jazz Pharmaceuticals; regulatory filing

Pressure On, Purpose Questioned as Second Round of FDA Priority Review Vouchers Revealed

3 weeks ago talkbio0Tagged Anemia, Sickle Cell, Biosimilars, Commissioner 's National Priority Voucher, Drug Approval, drug price, eli lilly, erbB-2 Receptor, Malignant neoplasm of lung, Obesity, Priority Review, public health medicine (field), Tuberculosis, Drug-Resistant, United States Food and Drug Administration, voucher program

FDA; Commissioner’s National Priority Voucher; priority review; drug approval; voucher program; Eli Lilly; Novo Nordisk; her2 lung cancer; obesity drugs; drug-resistant tuberculosis; sickle cell disease; biosimilars; public health; drug pricing; regulatory controversy

Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study

3 weeks ago talkbio0Tagged Antibodies, Bispecific, erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, orphan drug designation, Overall Survival, Pharmacotherapy, Phase 2 trial, Phase 3, practice-changing, Progression-Free Survival, Zanidatamab, Zymeworks

Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation

ChemDiv’s Discovery Platform Enables Differentiated, Reversible Pan-EGFR Kinase Inhibitors for GFR-Mutant Lung Cancer

1 month ago talkbio0Tagged Candidiasis, Chronic Mucocutaneous, ChemDiv, Discovery Platform, Drug Design, Epidermal Growth Factor Receptor, Kinase Inhibitors [MoA], Kinome, lead-optimization, Non-Small Cell Lung Carcinoma, Pan-EGFR Inhibitors, Readiness, selectivity, Wild-Type EGFR Sparing

ChemDiv; Discovery Platform; EGFR; Reversible Pan-EGFR Inhibitors; NSCLC; Kinase Inhibitors; Wild-Type EGFR Sparing; Kinome Selectivity; AI-Guided Drug Design; CMC Readiness; Lead Optimization

Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

2 months ago talkbio0Tagged ACR-2316, Acrivon, AP3, Conferences, Generative Phosphoproteomics, Inhibitor, KaiSR, partial response, PKMYT1 protein, human, Platform, PLK1 gene, precision oncology, preclinical data, Study models, WEE1 inhibitor

Acrivon Therapeutics; AP3 platform; Generative Phosphoproteomics; KaiSR model; ACR-2316; AACR-NCI-EORTC conference; preclinical data; partial response; WEE1 inhibitor; PKMYT1 inhibitor; PLK1; precision oncology

SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented at ESMO 2025

2 months ago talkbio0Tagged Antibody-Drug Conjugates, BL-B01D1 - 303, Epidermal Growth Factor Receptor, iza-bren, Nasopharyngeal carcinoma, ORR, Phase 3 Clinical Trials, SystImmune

SystImmune; iza-bren; BL-B01D1-303; Phase III trial; nasopharyngeal carcinoma; dual primary endpoints; ORR; antibody-drug conjugate (ADC); EGFR×HER3 bispecific; ESMO 2025

Recent Trends in Biomarker Testing for NSCLC: Maximizing Real-World Survival

2 months ago talkbio0Tagged ALK gene, biomarker testing, Epidermal Growth Factor Receptor, Liquid Biopsy, next-generation sequencing, Non-Small Cell Lung Carcinoma, Overall Survival, PD-L1, Precision Medicine, Real-world

NSCLC; biomarker testing; overall survival; PD-L1; EGFR; ALK; next-generation sequencing; liquid biopsy; precision medicine; real-world data

Servier Pays $210M Upfront for Ex-US Rights to Ideaya’s PKC Inhibitor Darovasertib

3 months ago talkbio0Tagged Clinical Trials, Darovasertib, Ideaya Biosciences, Inhibitor, milestone payments, oncology licensing deal, Protein Kinase C, Protein Kinase C Inhibitor, royalties, Servier, uveal melanoma

Servier; Ideaya Biosciences; darovasertib; protein kinase C inhibitor; PKC inhibitor; uveal melanoma; oncology licensing deal; clinical trials; milestone payments; royalties

AbbVie’s Rinvoq Achieves Strong Phase 3 Results in Alopecia Areata, Clearing Key Efficacy Milestone

4 months ago talkbio0Tagged AbbVie, Alopecia, hair regrowth, Inhibitor, Janus kinase, Rinvoq, Salts, Score, upadacitinib

AbbVie; Rinvoq; Phase 3 trial; alopecia areata; hair regrowth; upadacitinib; SALT score; JAK inhibitor